Tern’s portfolio company Wyld Networks signs contract with Bayer Crop Science

IoT

Tern Plc (LON:TERN), the investment company specialising in the Internet of Things, has noted that its portfolio company Wyld Networks AB has announced that it has signed a contract with Bayer Crop Science, a world leader in agriculture and part of the multinational Bayer Corporation.  Bayer has placed an initial purchase order worth SEK 320,000 (approximately £27,000) with Wyld Networks to develop a satellite IoT terminal and sensor to collect data from beehives.

Commenting Al Sisto, CEO of Tern, said:

“This is an important engagement for Wyld and we are very pleased that they are now working to develop a satellite IoT platform with Bayer. As Wyld’s CEO Alastair Williamson has pointed out, there is a substantial and growing market for affordable satellite IoT connectivity in multiple markets from agriculture, utilities, maritime and the environment and we look forward to Wyld’s continued progress”.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search